Current State of Cell Therapies for Breast Cancer

Cancer J. 2022 Jul-Aug;28(4):301-309. doi: 10.1097/PPO.0000000000000607.


Metastatic breast cancer (BC) is an aggressive form of cancer and is an absolute challenge to treat. This review discusses the standard treatments available for metastatic BC. It further highlights the rationale for targeting oncodrivers, tumor-associated antigens, and neoantigens in BC. Explaining the significance of immune response in successful immunotherapeutic studies, it draws attention towards how adoptive cell therapy can be a useful immunotherapeutic tool. We focus on adoptive cell therapy in BC covering tumor-infiltrating lymphocyte therapy, engineered T cell receptor therapy, chimeric antigen receptor therapy, dendritic cell therapy and natural killer cell therapy. In this work, we aim to provide an overview of clinical data regarding the use of cellular immunotherapies in BC. Eventually, we conclude by proposing future adoptive cell therapy approaches, which can be used to cure BC.

Trial registration: NCT03112590 NCT04111510.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / therapy
  • Cell- and Tissue-Based Therapy
  • Female
  • Humans
  • Immunotherapy
  • Immunotherapy, Adoptive
  • Receptors, Antigen, T-Cell


  • Receptors, Antigen, T-Cell

Associated data